Shares of Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.00 and traded as high as $0.24. Hemispherx BioPharma shares last traded at $0.23, with a volume of 1,440,226 shares traded.
Hemispherx BioPharma Stock Performance
Hemispherx BioPharma Company Profile
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
See Also
- Five stocks we like better than Hemispherx BioPharma
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- 3 Buy-and-Hold Stocks for Long-Term Growth
- 3 Small Caps With Big Return Potential
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png?v=20220915161652&h=45&w=95&zc=2){kind=logo}
